Medline Q1 sales up 10.7% to $7.4B; net income down 25.8%, adjusted EBITDA down 10.6%

Medline Inc.

2026-Q1 EPS reported $0.16 revenue$7,352,000,000

Net income $239M (-25.8% YoY); Diluted EPS $0.16; Adjusted Diluted EPS $0.33.
Organic sales growth 10.1%; total sales $7.4B driven by new customer signings and existing customer growth.
Adjusted EBITDA $776M (-10.6% YoY) on higher tariffs, operating expenses, and IPO-related bonus.
Raising full-year organic sales guidance to 8.5%-9.5% (prior 8%-9%); maintaining adjusted EBITDA outlook $3.5-$3.6B.
Free Cash Flow $316M; net cash from ops $412M, capex for distribution centers and manufacturing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Medline Inc. reported the three months ended March 28, 2026 results: revenue $7.4 billion, net income $239 million, EPS $0.16. Guidance raised.

Period: the three months ended March 28, 2026
Revenue: $7.4 billion
Net income: $239 million
EPS: $0.16
Guidance: raised
Result: preliminary results

Exact text from the filing

Net sales of $7.4 billion, an increase of 10.7% • Net income of $239 million, a decrease of 25.8%

View on SEC.gov

Browse all earnings releases →

Medline Inc. filing history →

Source: SEC EDGAR

accession 0002046386-26-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.